Literature DB >> 27344839

[Pestle needle at Yaoyangguan bazhen and Heche-mingqiang section for 31 cases of bi syndrome at low back].

Xuhao Liu, Yang Yu, Lei Zhong, Xiaohong Fan.   

Abstract

OBJECTIVE: To observe the clinical effect of pestle needle at Yaoyangguan bazhen and Heche-mingqiang section for bi syndrome (cold dampness type) at low back.
METHODS: Thirty-one patients of bi syndrome (cold dampness type) at low back were treated with pestle needle at Yaoyangguan bazhen and Heche-mingqiang section. After the treatment of pestle needle, traditional acupuncture was used at Shenshu (BL 23), Dachangshu (BL 25), Huantiao (GB 30), Weizhong (BL 40), Chengshan (BL 57), Kunlun (BL 60), etc., followed by TCM washing at low back and legs. Once daily, five days of treatment were taken as one course, and there was an interval of 2 days between two courses. Totally 4 courses were given. The visual analogue scale (VAS) before and after treatment was observed, and the clinical efficacy was evaluated.
RESULTS: The total effective rate was 90.3% (28/31) in 31 patients; the VAS after treatment was (2.42 ± 0.78), which was significantly, different from (5.59 ± 1.17) before treatment (P < 0.01). CONCLUSION The pestle needle at Yaoyangguan bazhen and Heche-mingqiang section is effective, noninvasive, painless for low-back bi syndrome (cold dampness type), and it is convenient for operation and easily accepted.

Entities:  

Mesh:

Year:  2016        PMID: 27344839

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  2 in total

1.  Pestle Needle (Chu Zhen)Treatment for Low-Back Pain and Sciatica.

Authors:  Willie Japaries; Aryaprana Nando
Journal:  Med Acupunct       Date:  2022-04-19

2.  The effect of the therapy of "combination 3 methods progression" in patients with neurogenic bowel dysfunction (constipated type): Study protocol for a randomized controlled trial.

Authors:  Qing Li; Yin-Li Shen; Yun-Lan Jiang; Dong-Shuang Li; Song Jin
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.